Diabetes, Vol 44, Issue 8 895-899, Copyright © 1995 by American Diabetes Association

ARTICLES

Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli

T Nakamura, I Ebihara, M Fukui, Y Tomino and H Koide
Department of Medicine, Juntendo University School of Medicine, Tokyo, Japan.

We have previously reported that the mRNA levels of extracellular matrix (ECM) components including alpha 1(I), alpha 1(III), and alpha 1(IV) collagen chains, laminin B1 and B2 chains, and growth factors including tumor necrosis factor (TNF)-alpha, platelet-derived growth factor (PDGF)-B chain, transforming growth factor (TGF)-beta, and basic fibroblast growth factor (FGF) all increase with age in diabetic glomeruli. The present study was designed to assess whether glomerular expression of these mRNAs in rat diabetic glomeruli is affected by a specific endothelin receptor A antagonist, FR139317. Diabetes was produced by streptozotocin injection, and animals were divided into four groups: untreated diabetic rats, FR139317-treated diabetic rats, control nondiabetic rats, and FR139317-treated control rats. FR139317 treatment was continued for 24 weeks. FR139317 attenuated the rise in creatinine clearance (P < 0.01) and reduced urinary protein excretion (P < 0.01) in diabetic rats, but did not affect blood pressure. FR139317 attenuated the increases in glomerular mRNA levels of alpha 1(I) (P < 0.01), alpha 1(III) (P < 0.01), and alpha 1(IV) (P < 0.01) collagen chains, laminin B1 (P < 0.01) and B2 (P < 0.01) chains, TNF-alpha (P < 0.01), PDGF-B (P < 0.01), TGF-beta (P < 0.001) and basic FGF (P < 0.01) in diabetic rats. However, FR139317 did not affect these mRNA levels in glomeruli of control rats. These findings suggest that FR139317 may be useful in the treatment of diabetic glomerulopathy by reducing mRNA levels of ECM components and growth factors.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. M. Sasser, J. C. Sullivan, J. L. Hobbs, T. Yamamoto, D. M. Pollock, P. K. Carmines, and J. S. Pollock Endothelin A Receptor Blockade Reduces Diabetic Renal Injury via an Anti-Inflammatory Mechanism J. Am. Soc. Nephrol., January 1, 2007; 18(1): 143 - 154. [Abstract] [Full Text] [PDF]

				J. Ortmann, P. C. Nett, J. Celeiro, R. Hofmann-Lehmann, L. Tornillo, L. M. Terracciano, and M. Barton Downregulation of renal endothelin-converting enzyme 2 expression in early autoimmune diabetes. Experimental Biology and Medicine, June 1, 2006; 231(6): 1030 - 1033. [Abstract] [Full Text] [PDF]

				S. Jesmin, S. Zaedi, N. Yamaguchi, S. Maeda, I. Yamaguchi, K. Goto, and T. Miyauchi Effects of dual endothelin receptor antagonist on antiapoptotic marker bcl-2 expression in streptozotocin-induced diabetic rats. Experimental Biology and Medicine, June 1, 2006; 231(6): 1034 - 1039. [Abstract] [Full Text] [PDF]

				B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines Endocr. Rev., December 1, 2004; 25(6): 971 - 1010. [Abstract] [Full Text] [PDF]

				F. N. Ziyadeh Mediators of Diabetic Renal Disease: The Case for TGF-{beta} as the Major Mediator J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S55 - 57. [Abstract] [Full Text]

				A. Sorokin and D. E. Kohan Physiology and pathology of endothelin-1 in renal mesangium Am J Physiol Renal Physiol, October 1, 2003; 285(4): F579 - F589. [Abstract] [Full Text] [PDF]

				L. C. Katwa Cardiac myofibroblasts isolated from the site of myocardial infarction express endothelin de novo Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1132 - H1139. [Abstract] [Full Text] [PDF]

				E. Tsiani, P. Lekas, I. G. Fantus, J. Dlugosz, and C. Whiteside High glucose-enhanced activation of mesangial cell p38 MAPK by ET-1, ANG II, and platelet-derived growth factor Am J Physiol Endocrinol Metab, January 1, 2002; 282(1): E161 - E169. [Abstract] [Full Text] [PDF]

				H. Hua, H. J. Goldberg, I.G. Fantus, and C. I. Whiteside High Glucose-Enhanced Mesangial Cell Extracellular Signal-Regulated Protein Kinase Activation and {alpha}1(IV) Collagen Expression in Response to Endothelin-1: Role of Specific Protein Kinase C Isozymes Diabetes, October 1, 2001; 50(10): 2376 - 2383. [Abstract] [Full Text]

				M. D. Apostolova, S. Chen, S. Chakrabarti, and M. G. Cherian High-glucose-induced metallothionein expression in endothelial cells: an endothelin-mediated mechanism Am J Physiol Cell Physiol, September 1, 2001; 281(3): C899 - C907. [Abstract] [Full Text] [PDF]

				S. Dhein, S. Hochreuther, C. a. d. Spring, K. Bollig, C. Hufnagel, and M. Raschack Long-Term Effects of the EndothelinA Receptor Antagonist LU 135252 and the Angiotensin-Converting Enzyme Inhibitor Trandolapril on Diabetic Angiopathy and Nephropathy in a Chronic Type I Diabetes Mellitus Rat Model J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 351 - 359. [Abstract] [Full Text]

				T Bodamyali, C R Stevens, M E J Billingham, S Ohta, and D R Blake Influence of hypoxia in inflammatory synovitis Ann Rheum Dis, December 1, 1998; 57(12): 703 - 710. [Full Text]

				S. Kassab, M. T. Miller, J. Novak, J. Reckelhoff, B. Clower, and J. P. Granger Endothelin-A Receptor Antagonism Attenuates the Hypertension and Renal Injury in Dahl Salt-Sensitive Rats Hypertension, January 1, 1998; 31(1): 397 - 402. [Abstract] [Full Text] [PDF]